BeOne Medicines Grants New RSUs to 188 Employees Under Incentive Plan

TipRanksMar 6 17:39

Express News | Zheng Shanjie: The output value related to the six major emerging pillar industries—integrated circuits, aerospace, biomedicine, and others—is expected to exceed 10 trillion yuan by 2030.

BreakingsMar 6 16:46

Orient Securities: Short-term volatility in the innovative drug sector may continue. It is recommended to actively seek investment opportunities at lower positions.

Overall, the performance of domestically produced drugs overseas has become a focal point of industry attention.

Zhitong FinanceMar 6 15:15

Hong Kong-listed innovative pharmaceutical companies are leveraging policy support. Institutions: The biopharmaceutical sector is transitioning from an 'R&D investment phase' to a 'value harvest phase.'

① Why has the biopharmaceutical sector recently attracted significant market attention? ② How do institutions view recent policies?

cls.cnMar 6 14:05

Surging BD transactions and policy catalysts! The Hang Seng Medicine ETF (159892) surged by 3.67%, while the HK Connect Healthcare ETF (520510) rose by 2.89%, with its real-time turnover rate ranking first among similar products.

Gelonghui, March 6th | Today, the innovative drug sector rebounded strongly. The constituent stock 3SBio Inc. surged by 10%, driving the Hang Seng Medicine ETF (159892) to rise by 3.67%. The Stock Connect Healthcare ETF (520510) increased by 2.89%, with a turnover rate of 54.58%, ranking first among similar products. In terms of news: ① The 2026 Government Work Report identifies new quality productive forces as a core focus, listing biomedicine alongside integrated circuits, aerospace, and low-altitude economy for the first time, clearly defining it as a national 'emerging pillar industry.' It is expected that innovative drugs will receive more concentrated policy support, funding, and resource allocation. ② Business development (BD) transactions continue.

Gelonghui FinanceMar 6 13:01

The innovative drug sector has rebounded strongly, driven by both policy support and industrial momentum, with the low-cost Hang Seng Stock Connect Innovative Drug ETF (E Fund) (159316) rising over 3%.

Gelonghui March 6th | The Hang Seng Stock Connect Innovative Pharmaceutical ETF (159316), managed by E Fund, surged over 3.9% in the morning session, becoming the top-performing sector-specific ETF during that period. From a news perspective, the industry is experiencing multiple catalysts. Policy catalyst: The government work report has mentioned innovative pharmaceuticals for three consecutive years, and biomedicine has been elevated to an 'emerging pillar industry.' In the 2026 government work report, biomedicine was, for the first time, listed alongside integrated circuits, aerospace, and low-altitude economy, clearly defined as a national 'emerging pillar industry.' With the elevation of strategic positioning, innovative pharmaceuticals are expected to receive more concentrated policy support, funding, and resource allocation. This is further reinforced by the report's proposal to 'launch commercial'

Gelonghui FinanceMar 6 10:55